Cholecalciferol supplementation lowers leptin and TMAO but increases NO and VEGF-A levels in obese vitamin D deficient patients: Is it one of the potential cardioprotective mechanisms of vitamin D?
Ozorowski M, Wiciński M, Wróbel Ł, Fajkiel-Madajczyk A
Nutrition & metabolism · 8 citations
Review labels
Neutral facts our review recorded about how this study was done. They describe method, never whether we like the result.
How it was studied
- Design
- Controlled clinical trial (classified by our AI screen)
- Studied in
- People
- Main outcome
- Mechanisms only
Who paid for it
- Funding
- Independent funding
Based on full-text disclosure statement.
Publication
- Published
- 2022-04-29 · Nutr Metab (Lond) · vol. 19 · issue 1 · p. 31
- Publisher
- BioMed Central
- Cited
- 12 citations · more than 84% of similar papers · 1.7× the field average
- References
- 75 works
- Access
- Open access (journal) · CC-BY
- Research areas
- Vitamin D Research Studies · Adipokines, Inflammation, and Metabolic Diseases · GDF15 and Related Biomarkers
- Keywords
- Medicine, Internal medicine, Leptin, Cholecalciferol, Vitamin D and neurology, Endocrinology, vitamin D deficiency, Vascular endothelial growth factor, Trimethylamine N-oxide, Obesity, Endothelial dysfunction, Inflammation, Vitamin, VEGF receptors, Chemistry, Trimethylamine, Biochemistry
4 authors
From PL
- Mateusz Ozorowski · correspondingNicolaus Copernicus University; Collegium Medicum in Bydgoszcz
- Michał WicińskiNicolaus Copernicus University; Collegium Medicum in Bydgoszcz
- Łukasz WróbelNicolaus Copernicus University; Collegium Medicum in Bydgoszcz
- Anna Fajkiel-MadajczykNicolaus Copernicus University; Collegium Medicum in Bydgoszcz
Abstract
Background
Vitamin D deficiency is one of the most common health issues in developed countries. Obese patients are most at risk of having serum 25-hydroxyvitamin D3 (25(OH)D3) levels that are too low due to the accumulation of vitamin D in adipose tissue. While the effects of a deficiency on the skeletal or immune system are known, the effects on the cardiovascular system are not yet clear. Our study investigates the effect of cholecalciferol supplementation in obese patients on selected biomarkers associated with cardiovascular diseases (CVDs).
Methods
The study enrolled 33 obese patients with insufficient 25(OH)D3 levels. For three months, the subjects supplemented with cholecalciferol at a dose of 2000 IU/day. Concentrations of nitric oxide (NO), vascular endothelial growth factor A (VEGF-A), leptin, trimethylamine N-oxide (TMAO) and soluble suppression of tumorigenicity 2 (sST2) were measured in baseline samples using ELISA (BioTek EPOCH). 25(OH)D3 levels measured on Beckman Coulter DXI 800 by chemiluminescence method.
Results
After supplementation, 25(OH)D3 levels increased significantly. Normal levels were achieved in most patients. A statistically significant reduction leptin and TMAO levels was observed. At the same time, NO and VEGF-A levels increased statistically significantly.
Conclusion
This study indicates that restoring normal 25(OH)D3 levels in obese people reduces the concentration of pro-inflammatory factors associated with cardiovascular diseases. Reducing inflammation and the potential impact on vascular reactivity leads to the conclusion that cholecalciferol supplementation in obese patients may benefit the cardiovascular system.
Abstract via Europe PMC. Copyright remains with the authors or publisher (CC BY).
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.